T0	Participants 108 160	locally advanced squamous cell head and neck cancer.
T1	Participants 300 362	locally advanced squamous cell carcinoma of the head and neck.
T2	Participants 363 549	One hundred and fifty-three patients (all of whom had stage III or IV unresectable disease with no distant metastases and who had received two cycles of taxol and cisplatin chemotherapy)
T3	Participants 1713 1765	patients with locally advanced head and neck cancer.